Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1994 1
1996 2
1998 1
2000 1
2001 3
2002 2
2003 2
2004 3
2005 2
2006 1
2007 2
2008 2
2009 3
2010 5
2011 1
2012 2
2013 1
2014 6
2015 3
2016 3
2017 3
2018 1
2019 3
2020 3
2021 1
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean j p ramon (2,506 results)?
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Viscardi G, et al. Eur J Cancer. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36368251 Review.
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, Pignon JP, Besse B; ANSELMA collaborative group. Remon J, et al. Eur J Cancer. 2022 May;166:112-125. doi: 10.1016/j.ejca.2022.02.002. Epub 2022 Mar 11. Eur J Cancer. 2022. PMID: 35286903 Review.

AA significantly prolonged OS (HR = 0.93 [95% confidence interval {CI}: 0.89; 0.98], p = 0.005) and PFS (0.80 [0.77; 0.84], p < 0.0001) compared with 2LT alone. ...Results were similar for PFS. AA increased the risk of hypertension (p < 0.0001), but not

…
AA significantly prolonged OS (HR = 0.93 [95% confidence interval {CI}: 0.89; 0.98], p = 0.005) and PFS (0.80 [0.77; 0.84], p …
Impact of Concurrent Genomic Alterations on Clinical Outcomes in Patients With ALK-Rearranged NSCLC.
Lara-Mejía L, Cardona AF, Mas L, Martin C, Samtani S, Corrales L, Cruz-Rico G, Remon J, Galvez-Nino M, Ruiz R, Rios-Garcia E, Tejada F, Lozano-Vazquez N, Rosell R, Arrieta O. Lara-Mejía L, et al. J Thorac Oncol. 2024 Jan;19(1):119-129. doi: 10.1016/j.jtho.2023.08.007. Epub 2023 Aug 10. J Thorac Oncol. 2024. PMID: 37572870
Compared with patients without coalterations, patients with concurrent CDKN2A/B loss (n = 21) had a shorter median progression-free survival (10.2 versus 34.2 mo, p < 0.001) and overall survival (26.2 versus 80.7 mo, p < 0.001). ...
Compared with patients without coalterations, patients with concurrent CDKN2A/B loss (n = 21) had a shorter median progression-free survival …
Development of an enteric-coated formulation containing freeze-dried, viable recombinant Lactococcus lactis for the ileal mucosal delivery of human interleukin-10.
Huyghebaert N, Vermeire A, Neirynck S, Steidler L, Remaut E, Remon JP. Huyghebaert N, et al. Eur J Pharm Biopharm. 2005 Aug;60(3):349-59. doi: 10.1016/j.ejpb.2005.02.012. Eur J Pharm Biopharm. 2005. PMID: 15927456
Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire, B.M. Goddeeris, E. Cox, J.P. Remon, and E. Remaut, Biological containment of genetically modified L. lactis for intestinal delivery of human interleukin-10, Nat. ...
Neirynck, N. Huyghebaert, V. Snoeck, A. Vermeire, B.M. Goddeeris, E. Cox, J.P. Remon, and E. Remaut, Biological contain …
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
Tagliamento M, Di Maio M, Remon J, Bironzo P, Genova C, Facchinetti F, Aldea M, Le Péchoux C, Novello S, Barlesi F, Besse B, Planchard D. Tagliamento M, et al. J Thorac Oncol. 2024 Jan;19(1):166-172. doi: 10.1016/j.jtho.2023.08.004. Epub 2023 Aug 9. J Thorac Oncol. 2024. PMID: 37567387

Comparing epithelioid versus nonepithelioid tumors, the objective response rate was 64.5% versus 46.4%, (p < 0.001) and the disease control rate was 92.3% versus 80.0%, (p = 0.043), with an OR of 2.56 (95% CI: 1.51-4.32) for disease response and of 3.37 (95% CI:

…

Comparing epithelioid versus nonepithelioid tumors, the objective response rate was 64.5% versus 46.4%, (p < 0.001) and the diseas

…
Evaluation of starch-maltodextrin-Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits.
Callens C, Remon JP. Callens C, et al. J Control Release. 2000 May 15;66(2-3):215-20. doi: 10.1016/s0168-3659(99)00271-0. J Control Release. 2000. PMID: 10742581
Bioavailabilities obtained with the powder formulations containing DDWM/Carbopol 974 P (5 and 10%) were significantly higher (p<0.05) than those containing maltodextrins-Carbopol 974 P mixtures. ...The bioavailability, t(max) and C(max) values of the formu …
Bioavailabilities obtained with the powder formulations containing DDWM/Carbopol 974 P (5 and 10%) were significantly higher (p …
Correlation between cryogenic parameters and physico-chemical properties of porous gelatin cryogels.
Van Vlierberghe S, Dubruel P, Lippens E, Cornelissen M, Schacht E. Van Vlierberghe S, et al. J Biomater Sci Polym Ed. 2009;20(10):1417-38. doi: 10.1163/092050609X12457418905508. J Biomater Sci Polym Ed. 2009. PMID: 19622280
In the present work, we have performed an in-depth physico-chemical and bio-physical evaluation of a series of previously described porous gelatin scaffolds (S. VanVlierberghe, V. Cnudde, P. Dubruel, B. Masschaele, A. Cosijns, I. DePaepe, P.J.S. Jacobs, L. Va …
In the present work, we have performed an in-depth physico-chemical and bio-physical evaluation of a series of previously described porous g …
Peripheral Refraction of Two Myopia Control Contact Lens Models in a Young Myopic Population.
Marcellán MC, Ávila FJ, Ares J, Remón L. Marcellán MC, et al. Int J Environ Res Public Health. 2023 Jan 10;20(2):1258. doi: 10.3390/ijerph20021258. Int J Environ Res Public Health. 2023. PMID: 36674016 Free PMC article.
Significant differences were found between RPR curves with both CLs in all the eccentricities (Bonferroni correction p < 0.008, except 10N). An incremental relationship between relative peripheral refraction at 30 degrees and myopia level was found. ...

Significant differences were found between RPR curves with both CLs in all the eccentricities (Bonferroni correction p < 0.008, ex

…
Rheological study on mucoadhesivity of some nasal powder formulations.
Callens C, Ceulemans J, Ludwig A, Foreman P, Remon JP. Callens C, et al. Eur J Pharm Biopharm. 2003 May;55(3):323-8. doi: 10.1016/s0939-6411(03)00024-9. Eur J Pharm Biopharm. 2003. PMID: 12754007
Various powder mixtures were used to administer insulin via the nasal route: a co-spray dried mixture of Amioca starch and Carbopol 974 P (1/3), drum dried waxy maize starch and Carbopol 974 P (9/1), maltodextrin DE38/Carbopol 974 P (9/1) and pure drum dried …
Various powder mixtures were used to administer insulin via the nasal route: a co-spray dried mixture of Amioca starch and Carbopol 974 P …
56 results